EADV 2026 Preview: Emerging Dermatology Therapies and Competitive Trends
EADV 2026 at a glance At 2026,will differentiation in dermatology move beyond…
DermaSensor AI dermatology devices | Lucid Diligence Brief
AI dermatology devices are advancing beyond validation studies as DermaSensor…
EADV Symposium 2026 Preview: Emerging Dermatology Trends and AI
EADV Symposium at a glance EADV Symposium 2026 in Athens highlights emerging…
AAD 2026 Preview: Dermatology Trends, Clinical Advances and AI
AAD 2026 at a glance AAD 2026 will highlight emerging dermatology trends across…
Lucid Diligence Brief: Novartis Rhapsido (remibrutinib) goes “beyond CSU”
Lucid Diligence Brief: Novartis Rhapsido (remibrutinib) goes “beyond CSU”…
Lucid Diligence Brief: Disc Medicine bitopertin FDA CRL
Lucid Diligence Brief: Disc Medicine bitopertin FDA CRL Professional audiences…
Lucid Diligence Brief: Nektar's REZPEG in atopic dermatitis
Lucid Diligence Brief: Nektar's REZPEG in atopic dermatitis Professional…
Lucid Diligence Brief: Kyowa Kirin regains rocatinlimab rights from Amgen
Lucid Diligence Brief: Kyowa Kirin regains rocatinlimab rights from Amgen…
Lucid Diligence Brief: Relation and Novartis atopic disease discovery alliance
Lucid Diligence Brief: Relation and Novartis atopic disease discovery alliance…
Lucid Diligence Brief: Pelage Pharmaceuticals $120M Series B
Lucid Diligence Brief: Pelage Pharmaceuticals $120M Series B Professional…
EADV 2025 Preview: Dermatology and Venereology Highlights to Watch
EADV 2025 at a Glance Ahead of EADV 2025, LucidQuest highlights…
Immunology Weekly News - May 28th 2025
🧠 This Week in Immunology: CBD for UVA, CAR-T for Autoimmune, and Real-World…